These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36285515)

  • 1. Nivolumab-induced radiation recall pneumonitis in non-small-cell lung cancer patients with thoracic radiation therapy.
    Noda-Narita S; Naito T; Udagawa H; Goto K; Miyawaki T; Mamesaya N; Nakashima K; Kenmotsu H; Shimokawaji T; Kato T; Hakozaki T; Okuma Y; Nakamura M; Nakayama Y; Watanabe H; Kusumoto M; Ohe Y; Horinouchi H
    Cancer Sci; 2023 Feb; 114(2):630-639. PubMed ID: 36285515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
    Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
    Front Immunol; 2022; 13():918787. PubMed ID: 35795657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer.
    Ding X; Ji W; Li J; Zhang X; Wang L
    Radiat Oncol; 2011 Mar; 6():24. PubMed ID: 21375774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
    Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
    Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
    Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
    BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
    Kharofa J; Cohen EP; Tomic R; Xiang Q; Gore E
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):238-43. PubMed ID: 22300564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
    Tamiya A; Tamiya M; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Inoue T; Okishio K; Nishino K; Kumagai T; Suzuki H; Hirashima T; Imamura F; Atagi S
    Anticancer Res; 2017 Sep; 37(9):5199-5205. PubMed ID: 28870955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey.
    Hata H; Mio T; Yamashita D; Matsumura C; Chisaki Y; Motohashi H; Yano Y
    Cancer Control; 2020; 27(4):1073274820977200. PubMed ID: 33297768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review.
    Wang M; Xu S; Zhu H
    Front Immunol; 2022; 13():823767. PubMed ID: 35280981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma.
    Nakamura K; Okubo K; Takahashi T; Mitsumori K; Ishigaki T; Ohnishi H
    IJU Case Rep; 2019 Jan; 2(1):30-33. PubMed ID: 32743367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer.
    Miyamoto S; Nomura R; Sato K; Awano N; Kuse N; Inomata M; Izumo T; Terada Y; Furuhata Y; Bae Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Feb; 49(2):160-164. PubMed ID: 30452687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 13. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
    Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J
    Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis.
    Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Hanai N; Muro K; Hida T
    BMC Cancer; 2021 Aug; 21(1):924. PubMed ID: 34399710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
    Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Yatabe Y; Hida T
    Lung Cancer; 2018 Nov; 125():212-217. PubMed ID: 30429022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.
    Ye X; Yang J; Stebbing J; Peng L
    BMC Pulm Med; 2022 Feb; 22(1):54. PubMed ID: 35123465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.
    Saito S; Abe T; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Yamaguchi O; Kaira K; Kagamu H; Noda SE; Kato S
    J Radiat Res; 2021 Jul; 62(4):669-675. PubMed ID: 34121123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential benefits of volumetric modulated arc therapy to reduce the incidence of ≥ grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients.
    Imano N; Kimura T; Kawahara D; Nishioka R; Fukumoto W; Kawano R; Kubo K; Katsuta T; Takeuchi Y; Nishibuchi I; Murakami Y; Horimasu Y; Masuda T; Fujitaka K; Hattori N; Nagata Y
    Jpn J Clin Oncol; 2021 Dec; 51(12):1729-1735. PubMed ID: 34625805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.